InnoTherapy Inc (246960) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InnoTherapy Inc (246960) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-107.41 Million ≈ $-72.79K USD) by net assets (₩24.57 Billion ≈ $16.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 246960 company net worth for the company's overall valuation and market capitalisation.
InnoTherapy Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InnoTherapy Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InnoTherapy Inc ranked by their cash flow conversion efficiency. Explore InnoTherapy Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
0.044x |
|
Medifron DBT Co. Ltd
KQ:065650
|
-0.472x |
|
Salutica Bhd
KLSE:0183
|
-0.102x |
|
Adriatic Metals
LSE:ADT1
|
0.000x |
|
Tira Austenite Tbk
JK:TIRA
|
0.003x |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
-0.031x |
|
Smartiks Yazilim AS
IS:SMART
|
0.098x |
|
Mg Internation
PA:ALMGI
|
-0.026x |
Annual Cash Flow Conversion Efficiency for InnoTherapy Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of InnoTherapy Inc from 2015 to 2024. View InnoTherapy Inc (246960) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩15.52 Billion ≈ $10.52 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.384x | -157.47% |
| 2023-12-31 | ₩18.90 Billion ≈ $12.81 Million |
₩-2.82 Billion ≈ $-1.91 Million |
-0.149x | +52.60% |
| 2022-12-31 | ₩13.05 Billion ≈ $8.84 Million |
₩-4.10 Billion ≈ $-2.78 Million |
-0.315x | +20.39% |
| 2021-12-31 | ₩10.08 Billion ≈ $6.83 Million |
₩-3.98 Billion ≈ $-2.70 Million |
-0.395x | -78.14% |
| 2020-12-31 | ₩12.94 Billion ≈ $8.77 Million |
₩-2.87 Billion ≈ $-1.95 Million |
-0.222x | -2.53% |
| 2019-12-31 | ₩15.08 Billion ≈ $10.22 Million |
₩-3.26 Billion ≈ $-2.21 Million |
-0.216x | +5.49% |
| 2018-12-31 | ₩9.52 Billion ≈ $6.45 Million |
₩-2.18 Billion ≈ $-1.48 Million |
-0.229x | +68.62% |
| 2017-12-31 | ₩3.10 Billion ≈ $2.10 Million |
₩-2.26 Billion ≈ $-1.53 Million |
-0.730x | -294.88% |
| 2016-12-31 | ₩6.07 Billion ≈ $4.12 Million |
₩-1.12 Billion ≈ $-760.70K |
-0.185x | -200.06% |
| 2015-12-31 | ₩-6.23 Billion ≈ $-4.22 Million |
₩-1.15 Billion ≈ $-779.63K |
0.185x | -- |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more